Sandoz continues to go through an exciting and transformative period as a global leader and pioneering provider of sustainable Biosimilar and Generic medicines. As we continue down this new and ambitious path, unique opportunities will present themselves, both professionally and personally. Join us, the future is ours to shape!
Primary responsibilities are accurately adjudicating commercial contracts for various market segments housed in SAP and Model N, based upon proper evaluation and interpretation. Ensuring the accurate, timely system set up and payment of complex contractual rebate obligations to medium to large Wholesaler, Retail, and Institutional customers, Pharmacy and Benefit Management (PBM’s). The role also requires to manage special projects
Generic and Biosimilar medicines are the backbone of the global medicines industry. Sandoz, a leader in this sector, provided more than 900 million patient treatments across 100+ countries in 2024 and while we are proud of this achievement, we have an ambition to do more!
With investments in new development capabilities, production sites, new acquisitions, and partnerships, we have the opportunity to shape the future of Sandoz and help more patients gain access to low-cost, high-quality medicines, sustainably.
Our momentum is powered by an open, collaborative culture driven by our talented and ambitious colleagues, who, in return for applying their skills experience an agile and collegiate environment with impactful, flexible-hybrid careers, where diversity is welcomed and where personal growth is supported!
Join us!
We are committed to building an outstanding, inclusive work environment and diverse teams representative of the patients and communities we serve.
Ability To Influence Key Stakeholders, Compliance And Controls, Data Cleansing Normalization, Data Visualization, Employee Engagement, Financial And Management Reporting, Market Understanding, Planning & Analysis, Process Optimization, Understanding Value Drivers

Sandoz is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients.
More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz annually, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer.
Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion.
Read our community engagement guidelines: http://bit.ly/4ofoggc